Best Oncology Companies in North Carolina, United States

Developer of gene editing therapies to treat rare genetic diseases. The company utilizes novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination. The company's pipeline include therapies for Hepatitis B, duchenne muscular dystrophy, and more.

A next-generation cell cycle control company advancing precision treatments for cancer. The company’s lead compound, INX-315, is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor entering clinical development and has therapeutic targets across many tumor types, including ovarian, breast, and lung cancers.

Funding rounds

• Apr 2026Series B$5M
• Aug 2025Series B$11.2M
• Mar 2022Series B$30M

Founders & team

Patrick RobertsCo-Founder & CEOJay StrumCo-FounderJohn BisiCo-Founder

Investors

Boxer Capital, RA Capital Management, Eshelman Ventures, Lilly, Pharmacosmos, Cape Fear BioCapital

Developer of drug discovery and precision therapy platform for oncology. The company has micro-organ sphere technologies which enable rapid diagnostics, personalized drug screening, and scalable patient-derived models for immuno-oncology drug discovery.

Funding rounds

• Apr 2025Series B$19.4M
• Apr 2025Conventional Debt—
• Feb 2025Grant (prize money)$2.4M
• Jul 2022Series A$19M

Founders & team

Hans CleversCo-Founder

Investors

Alexandria, EQT, Mubadala, Pear VC, Google Ventures, Duke University

Tech stack

CookieyesCore-JsElementorGoogle WorkspaceHello ElementorJquery

Developer of diagnostics for cancer classification and treatment. The core technology, Cancer Subtype Platform (CSP) identifies biologic subtypes through an integrated analysis of tumor genomics. The lead product, the first-generation Lung Subtyping Predictor (LSPTM) classifies tumors into squamous, adenocarcinoma, and neuroendocrine (small cell and carcinoid) lung cancer.

Developer of thymus-based therapies for immune-mediated diseases to increase healthspan. It focuses on preserving, restoring, and manipulating the function of the thymus. The thymus is a master regulator of immune tolerance. The company aims to control immune tolerance by influencing thymus function.

Funding rounds

• Dec 2024Seed$20.2M
• Oct 2024Seed$17.2M

Founders & team

Holger RussScientific Co-FounderFrancisco LeonFounder

Investors

Columbus Venture Partners, Criteria Bio Ventures, Sessa Capital, BioAdvance, Ben Franklin Technology Partners, Pacific 8 Ventures

Blood test for early breast cancer detection in dense breast tissue. The company develops innovative diagnostic and therapeutic products focused on cancer, particularly addressing unmet needs in detection and treatment. They utilize cutting-edge, patented technology to target tumor-associated MUC1 (tMUC1), a key cancer antigen. Their lead product, Agkura® Personal Score, is a simple blood test aiding breast cancer detection in women with dense breast tissue, where mammography alone is often insufficient. The company is also developing agents for tumor imaging and targeted drug delivery, aiming to improve cancer outcomes. Their business model centers on research and commercialization through strategic partnerships. This is a B2C and B2B healthcare and diagnostic company.

Funding rounds

• May 2025Grant (prize money)$400K
• Sep 2021Grant (prize money)$260.6K
• Sep 2021Grant (prize money)$400K

Founders & team

Rahul PuriCo-Founder & CEO

Investors

HHS

Developer of therapeutics for cancer treatment. It offers SAGUARO technology that provides microRNA replacement therapy, which include a lead candidate (TT-003) for the treatment of glioblastoma via intratumoral delivery.

Funding rounds

• Mar 2025Grant (prize money)$275.8K
• Sep 2022Grant (prize money)$275.8K

Founders & team

Pierpaolo PeruzziCo-FounderE ChioccaCo-Founder

Investors

HHS

Argos Therapeutics, previously known as Merix Bioscience, develops RNA-based autologous dendritic cell therapies for cancer and infectious disease. It uses its proprietary ARCELIS platform to 'train' the patient's dendritic cells and stimulate an in vivo tumor-specific immune response. Its lead candidate is in phase III trials for metastatic renal cell carcinoma, while another candidate (AGS-004) in combination with the latency reversing drug vorinostat, is in investigator initiated phase II clinical trials for HIV. The company has received funding from the NIH, NIAID and the Collaboratory of Research for AIDS Eradication.

Developer of therapeutic solutions for the treatment of different cancer. The company has its proprietary kinase drug discovery platform to advance a pipeline of first-in-class compounds and best-in-class drug candidates. Its drug pipeline includes G1T28, a CDK4/6 inhibitor that is being developed to reduce bone marrow and immune system damage caused by chemotherapy, and G1T38, a CDK4/6 inhibitor that is being developed to treat patients with CDK4/6-dependent tumors. Investigating G1T28 in clinical trials in patients with small-cell lung cancer and G1T38 in estrogen receptor breast cancer patients and castrate-resistant prostate cancer patients.

Developer of viral vaccines and antibody-drug conjugates for the treatment of cancer. The company has two platforms in clinical development: Polio Virus Sabin-Rhinovirus Poliovirus (PVS-RIPO) and Antibody-Directed Immuno-Conjugates (ADC). Its drug pipeline includes PVS-RIPO, a viral vaccine for Glioblastoma (Phase 2), D2C7-IT, an ADC for Glioblastoma (Phase 1). PVS-RIP) is also being developed for breast and melanoma (Preclinical). The company has licensed its technology platforms from Duke University.

Funding rounds

• Apr 2021Series B$43.5M
• May 2017Series A$1.1M
• Feb 2017Series A$4M

Founders & team

Matthias GromeierFounderDarell BignerFounder

Investors

Pappas Capital

Provider of liquid biopsy tests using CTCs. The flagship system uses a capture bed coated with specific antibodies to capture and separate CTCs from blood samples for analysis. The system has been clinically validated for pancreatic cancer, colorectal cancer, ovarian cancer, and breast cancer.

Funding rounds

• Mar 2022Grant (prize money)—
• Dec 2021Series B$6M
• Aug 2021Grant (prize money)$250K
• Mar 2021Series B$6M

Founders & team

Steven SoperCo-Founder & CTOGreg StuddardChief Executive Officer

Investors

Mizzou, NIH, HHS

CoImmune specializes in the development of immuno-oncology therapies based on its two proprietary platform technologies. The autologous RNA-loaded dendritic cell technology for solid tumors specifically targets each patient’s unique tumor antigens. The allogeneic CAR-CIK technology is a variation on CAR-T therapy with greatly reduced toxicity while retaining strong efficacy based on an on-going clinical trial in pediatric and adult acute lymphoblastic leukemia patients.